Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Blood (2024) 143 (14): 1391–1398.

https://doi.org/10.1182/blood.2023021752

Published: 2024

Includes: Supplemental data

Journal Articles

Molecular Subtypes in BCR::ABL1 -Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events

Blood (2023) 142 (Supplement 1): 843.

https://doi.org/10.1182/blood-2023-187315

Published: 2023

Journal Articles

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Nicola Goekbuget, Stefan Schwartz, Christoph Faul, Max S. Topp, Marion Subklewe, Andrea Renzelmann, Andrea Stoltefuss, Bernd Hertenstein, Anne Wilke, Simon Raffel, Nadja Jäkel, Vladan Vucinic, Dirk Markus Niemann, Lena Reiser, Hubert Serve, Monika Brüggemann, Andreas Viardot

Blood (2023) 142 (Supplement 1): 964.

https://doi.org/10.1182/blood-2023-180472

Published: 2023

Journal Articles

Prospective Evaluation of Patient-Reported Outcome up to 10 Years after Allogeneic Stem Cell Transplantation Using FACT-G/BMT and EORTC-QLQ30 Questionnaires

Sina Alexandra Beer, Johanna Blaettel, Kristina Reuss, Jan Christian Schröder, Wichard Vogel, Christoph Faul, Wolfgang Andreas Bethge, Claudia Lengerke

Blood (2023) 142 (Supplement 1): 2208.

https://doi.org/10.1182/blood-2023-188833

Published: 2023

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Adult Metachromatic Leukodystrophy (MLD): A Case Series

Andreas Riedel, Christoph Faul, Kristina Reuss, Peter Lang, Claudia Lengerke, Nadine Weissert, Holger Hengel, Ludger Schoels, Wolfgang Andreas Bethge

Blood (2023) 142 (Supplement 1): 7115.

https://doi.org/10.1182/blood-2023-187317

Published: 2023

Journal Articles

Patients with High-Risk Myelodysplastic Neoplasms Do Not Benefit from Remission Induction with Azacitidine Prior to Hematopoietic Cell Transplantation: A Retrospective, Single-Center Analysis with Extended Follow-up

Jan Christian Schröder, Jan Frederic Weller, Philipp Faustmann, Lucas Mix, Christoph Faul, Claudia Lengerke, Wolfgang Andreas Bethge

Blood (2023) 142 (Supplement 1): 2231.

https://doi.org/10.1182/blood-2023-174430

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplant Recipients Carrying DNMT3A and ASXL1 Mutations More Frequently Develop Severe Graft Versus Host Disease and Arterial Hypertension

Alisha Weiss-Haug, Reka A Haraszti, Britta Merz, Kristina Reuss, Christoph Faul, Wolfgang Andreas Bethge, Frederike Schwartz, Wichard Vogel, Claudia Lengerke

Blood (2023) 142 (Supplement 1): 3564.

https://doi.org/10.1182/blood-2023-188752

Published: 2023

Journal Articles

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Blood (2022) 140 (Supplement 1): 115–117.

https://doi.org/10.1182/blood-2022-158381

Published: 2022

Journal Articles

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Blood (2021) 138 (24): 2499–2513.

https://doi.org/10.1182/blood.2020010543

Published: 2021

Includes: Supplemental data

Journal Articles

Expression of CD20 Affects Early MRD Response to Rituximab in Adult B Cell Precursor Lymphoblastic Leukemia of the GMALL 08/2013 Trial

Monika Szczepanowski, Johanna Richter, Miriam Kelm, Heiko Trautmann, Britta Kehden, Matthias Ritgen, Christoph Faul, Kathrin Nachtkamp, Björn Steffen, Andreas Viardot, Johannes Gärtner, Johannes Duell, Claudia D. Baldus, Stefan Schwartz, Nicola Goekbuget, Monika Brüggemann

Blood (2021) 138 (Supplement 1): 2301.

https://doi.org/10.1182/blood-2021-150375

Published: 2021

Journal Articles

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Blood (2021) 138 (Supplement 1): 362.

https://doi.org/10.1182/blood-2021-146306

Published: 2021

Journal Articles

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial

Nicola Goekbuget, Andrea Stoltefuß, Max Topp, Stefan Schwartz, Andrea Renzelmann, Christoph Faul, Bernd Hertenstein, Vladan Vucinic, Maria Wachsmuth, Anne C Wilke, Lena Baumann, Diana Tichy, Monika Brüggemann, Andreas Viardot

Blood (2021) 138 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2021-146214

Published: 2021

Journal Articles

Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

Blood (2021) 138 (Supplement 1): 3926.

https://doi.org/10.1182/blood-2021-152349

Published: 2021

Journal Articles

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137350

Published: 2020

Journal Articles

Molecular Subtypes with Distinct Clinical Phenotypes and Actionable Targets in Adult B Cell Precursor ALL Treatment According to GMALL Protocols

Lorenz Bastian, Sonja Hänzelmann, Martin Neumann, Alina Hartmann, Thomas Burmeister, Stefan Schwartz, Walter Fiedler, MD, Mustafa Kondakci, MD, Andreas Viardot, Professor Dr, Folker Schneller, Christoph Faul, MD, Max S. Topp, MD, Sören Franzenburg, Andre Franke, Heiko Trautmann, PhD, Nicola Goekbuget, MD, Monika Brüggemann, MD, Claudia D Baldus, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-143032

Published: 2020

Journal Articles

Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies

Kai Rejeski, MD, Carolina Berger, Liv Jentzsch, Semjon Willier, MD, Viktoria Blumenberg, MD, Veit Buecklein, MD, Christoph Faul, MD, Christian Schmidt, MD, Michael von Bergwelt, MD PhD, Tobias Feuchtinger, MD, Wolfgang Bethge, MD, Francis A. Ayuk, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141833

Published: 2020

Journal Articles

Autoantibody Mediated Desialylation Impairs Human Thrombopoiesis and Platelet Life Span

Irene Marini, Jan Zlamal, Lisann Pelzel, Wolfgang Bethge, Christoph Faul, MD, Ursula Holzer, PD Dr. MD, Karina Althaus, Tamam Bakchoul, Prof. Dr.

Blood (2019) 134 (Supplement_1): 2346.

https://doi.org/10.1182/blood-2019-131725

Published: 2019

Journal Articles

Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy

Michaela Kotrova, MD PhD, Monika Szczepanowski, PhD, Henrik Knecht, PhD, Christoph Faul, MD, Mustafa Kondakci, MD, Björn Steffen, MD, Andreas Viardot, MD, Michael Kneba, Dieter Hoelzer, MD PhD, Nicola Goekbuget, MD, Nikos Darzentas, PhD, Monika Brüggemann

Blood (2018) 132 (Supplement 1): 1555.

https://doi.org/10.1182/blood-2018-99-112844

Published: 2018

Journal Articles

Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases

Blood (2018) 132 (Supplement 1): 660.

https://doi.org/10.1182/blood-2018-99-111954

Published: 2018

NARROW

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR :: ABL1 -positive ALL

Molecular Subtypes in BCR::ABL1 -Positive ALL Are Defined By Cellular Origins and Cooperating Genomic Events

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial

Prospective Evaluation of Patient-Reported Outcome up to 10 Years after Allogeneic Stem Cell Transplantation Using FACT-G/BMT and EORTC-QLQ30 Questionnaires

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Allogeneic Hematopoietic Stem Cell Transplantation for Adult Metachromatic Leukodystrophy (MLD): A Case Series

Patients with High-Risk Myelodysplastic Neoplasms Do Not Benefit from Remission Induction with Azacitidine Prior to Hematopoietic Cell Transplantation: A Retrospective, Single-Center Analysis with Extended Follow-up

Allogeneic Hematopoietic Cell Transplant Recipients Carrying DNMT3A and ASXL1 Mutations More Frequently Develop Severe Graft Versus Host Disease and Arterial Hypertension

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Expression of CD20 Affects Early MRD Response to Rituximab in Adult B Cell Precursor Lymphoblastic Leukemia of the GMALL 08/2013 Trial

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial

Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Molecular Subtypes with Distinct Clinical Phenotypes and Actionable Targets in Adult B Cell Precursor ALL Treatment According to GMALL Protocols

Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies

Autoantibody Mediated Desialylation Impairs Human Thrombopoiesis and Platelet Life Span

Monitoring of the Clonal Architecture of B-Cell Precursor ALL during Induction Chemoimmunotherapy

Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only